Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Partially Remote
Drugs
Locations
Clinical Specialty
401-420 of 998 trials

High-Risk Neuroblastoma: Naxitamab and GM-CSF Treatment

We are studying a new treatment combining naxitamab and GM-CSF for children with high-risk neuroblastoma who have not responded to prior therapies. The trial aims to assess how well this treatment works and its safety.

Recurrent Neuroblastoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncologyPediatrics

Multiple Myeloma: AZD0305 Treatment Study

We are investigating whether AZD0305, alone or with other cancer therapies, is safe and effective for adults with relapsed or refractory multiple myeloma.

Relapsed or Refractory Multiple MyelomaSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHematologyOncology

Metastatic Breast Cancer: FDG-PET/CT vs. Conventional CT

We are studying whether FDG-PET/CT can better monitor treatment response in metastatic breast cancer patients compared to conventional CT. This may help improve survival and quality of life for those involved.

Metastatic Breast Cancer>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboStandard MedicinesPartially RemoteOncology

Preventing Blood Clots: REGN9933 and REGN7508 Study

We are studying two new medications to see if they can help prevent blood clots in adults with a peripherally inserted central catheter. The trial will also assess how safe these treatments are.

Venous Thromboembolism3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyHematology

Systemic Lupus Erythematosus: SAR441344 Treatment Study

We are investigating a new medication for people with Systemic Lupus Erythematosus to see if it helps reduce disease activity and improve symptoms compared to a placebo.

Systemic Lupus Erythematosus6-12 monthsEfficacy phase (II)16-20 visitsInvestigational MedicinesPartially RemoteInternal MedicineRheumatology

Colorectal Cancer: PD L 506 Oral Medication Study

We are investigating the safety of a new oral medication for patients with colorectal cancer and healthy volunteers. The study also looks at whether urine tests can help in diagnosing colorectal cancer.

Colorectal Cancer6-12 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesPartially RemoteInternal MedicineOncology

Primary IgA Nephropathy: Long-Term Study of Iptacopan

We are evaluating the long-term safety and tolerability of iptacopan in adults with primary IgA nephropathy. This study follows participants who have completed an earlier trial to see how well the treatment works over time.

IgA Nephropathy>2 yearsConfirmation phase (III)Monitoring phase (IV)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNephrology

Acute Progressive Stroke: Norepinephrine Treatment

We are studying whether adding norepinephrine to standard care helps improve recovery in patients with acute progressive perforating artery stroke. The goal is to see if this combination leads to better functional outcomes and reduces complications.

Ischemic Stroke>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesPartially RemoteInternal MedicineNeurology

Advanced Non-Small Cell Lung Cancer: New Immunotherapy Combinations

We are evaluating new combinations of immunotherapy for adults with untreated advanced non-small cell lung cancer. The goal is to see if these combinations are safe and more effective than standard treatment.

Non-small Cell Lung Cancer>2 yearsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteOncology

Chronic Rhinosinusitis: Lebrikizumab Study

We are testing a new medication, lebrikizumab, for people with chronic rhinosinusitis and nasal polyps who are already using nasal corticosteroids. The study aims to see if it can improve nasal congestion and reduce polyp severity.

Chronic Rhinosinusitis with Nasal Polyps1-2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Erosive Esophagitis: Oral Pantoprazole for Kids and Teens

We are studying how well oral pantoprazole works for maintaining healing in children and teens aged 1 to 17 with erosive esophagitis. We also want to understand its safety and how well they tolerate the treatment.

Erosive Esophagitis6-12 monthsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteGastroenterologyPediatrics

Heart Failure: Stopping Beta-Blockers

We are studying whether discontinuing beta-blockers is as safe for patients with improved heart function as continuing the medication. This trial aims to understand the effects on heart failure relapse and overall heart health.

Heart Failure>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Refractory Focal Onset Epilepsy: BHV-7000 Safety Study

We are evaluating the safety and tolerability of BHV-7000 in adults with refractory focal onset epilepsy. This study aims to ensure the treatment is safe for those who have not found relief with other options.

Focal Epilepsy1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Familial Chylomicronemia Syndrome: AKCEA-APOCIII-LRX Study

We are testing a new subcutaneous treatment for patients with Familial Chylomicronemia Syndrome who have previously used volanesorsen. The study aims to evaluate its safety and how well it is tolerated.

Familial Chylomicronemia Syndrome>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyHematology

Perennial Allergic Rhinitis: Lebrikizumab Study

We are testing a new medication, lebrikizumab, to see if it helps adults with perennial allergic rhinitis experience fewer nasal symptoms. This study compares its effects to a placebo treatment.

Perennial Allergic RhinitisConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteAllergologyOtolaryngologyPulmonology

Epidermolysis Bullosa Simplex: Diacerein 1% Ointment

We are studying a new ointment for people with generalized Epidermolysis Bullosa Simplex to see if it helps improve skin condition and reduce symptoms. The trial includes both adults and children aged 6 months and older.

Epidermolysis Bullosa Simplex1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatology

Knee Osteoarthritis: Genicular Arteries Embolization Study

We are investigating whether a new procedure can help reduce knee pain in people with symptomatic knee osteoarthritis. Participants will compare this treatment to a sham procedure to assess its effectiveness.

Knee Osteoarthritis>2 yearsConfirmation phase (III)6-10 visitsStandard MedicinesPartially RemoteInternal MedicineOrthopedics and Traumatology

Juvenile Idiopathic Arthritis: Bimekizumab Study

We are studying the safety and how bimekizumab moves in the body for children aged 2 to under 18 with certain types of juvenile idiopathic arthritis. This research aims to help improve treatment options for these young patients.

Juvenile Arthritis and Related Conditions6-12 monthsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemotePediatricsRheumatology

Staccato Alprazolam for Prolonged Seizures in Ages 12 and Up

We are studying the safety of Staccato Alprazolam for treating long seizures in children and adults. This trial will help us learn how well it works and its effects on lung health over time.

Prolonged Seizure>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Heart Failure: Finerenone and SGLT2 Inhibitor Study

We are investigating whether a combination of finerenone and an SGLT2 inhibitor can improve health outcomes for hospitalized heart failure patients. This study aims to see if this approach leads to better symptom relief and fewer hospital visits.

Heart Failure1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine